Effect of Atorvastatin (Lipitor) on Myocardial Apoptosis and Caspase-8 Activation Following Coronary Microembolization

Cell Biochemistry and Biophysics

Volumn 61, Issue 2, 2011, Pages 399-406

  Li, Lang ^a   Su, Qiang ^a   Wang, Yan ^a   Dai, Rixin ^a   Lu, Yongguang ^a   Su, Bo ^a   Zhao, Yongxiang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Atorvastatin; Coronary microembolization; Death receptor

Indexed keywords

ATORVASTATIN; CASPASE 3; CASPASE 8; DEATH RECEPTOR; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; ARTIFICIAL EMBOLISM; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG EFFECT; ENZYME ACTIVATION; HEART; HEART MUSCLE; MALE; METABOLISM; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 8; CORONARY VESSELS; EMBOLIZATION, THERAPEUTIC; ENZYME ACTIVATION; HEART; HEPTANOIC ACIDS; MALE; MYOCARDIUM; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DEATH DOMAIN;

ANIMALIA; RATTUS;

EID: 80955166082     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9199-z     Document Type: Article

References (19)

1. Kawano, H., Hayashida, T., Ohtani, H., et al. (2005). Histopathological findings of the no-reflow phenomenon following coronary intervention for acute coronary syndrome. International Heart Journal, 46, 327-332.
2. Jaffe, R., Charron, T., Puley, G., Dick, A., & Strauss, B. H. (2008). Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation, 117, 3152-3156.
3. Itsuro, M., Takahito, S., Kenji, O., et al. (2000). Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. Journal of the American College of Cardiology, 36, 1202-1209.
4. Grube, E., Schofer, J. J., Webb, J., et al. (2002). Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. American Journal of Cardiology, 89, 941-945.
5. Patti, G., Pasceri, V., Colonna, G., et al. (2007). Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. Journal of the American College of Cardiology, 49, 1272-1278.
6. Pasceri, V., Patti, G., Nusca, A., et al. (2004). Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) Study. Circulation, 110, 674-678.
7. Scalia, R. (2005). Statins and the response to myocardial injury. American Journal of Cardiovascular Drugs, 5, 163-170.
8. Thielmann, M., Dörge, H., Martin, C., et al. (2002). Myocardial dysfunction with coronary microembolization: Signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha and sphingosine. Circulation Research, 90, 807-813.
9. Kalenikova, E. I., Gorodetskaya, E. A., Zacharova, N. V., Shechter, A. B., & Medvedev, O. S. (1998). Perindopril effects on angiotensin I elimination in lung after experimental myocardial injury induced by intracoronary microembolization in rats. Journal of Cardiovascular Pharmacology, 32, 608-615.
10. Bajt, M. L., Lawson, J. A., Vonderfecht, S. L., Gujral, J. S., & Jaeschke, H. (2000). Protection against Fas receptor-mediated apoptosis in hepatocytes and nonparenchymal cells by a caspase-8 inhibitor in vivo: Evidence for a postmitochondrial processing of caspase-8. Toxicological Sciences, 58, 109-117.
11. Schiller, N. B., Acquatella, H., Ports, T. A., et al. (1979). Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation, 60, 547-555.
12. Zhang, Q. Y., Ge, J. B., Chen, J. Z., et al. (2006). Mast cell contributes to cardiomyocyte apoptosis after coronary microembolization. Journal of Histochemistry and Cytochemistry, 54, 515-523.
13. Bell, R. M., & Yellon, D. M. (2003). Atorvastatin, administrated at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by regulating a prosurvival pathway. Journal of the American College of Cardiology, 41, 508-515.
14. Mensah, K., Mocanu, M. M., & Yellon, D. M. (2005). Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment. Journal of the American College of Cardiology, 45, 1287-1291.
15. Fonarow, G. C., Wright, R. S., Spencer, F. A., et al. (2005). Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. American Journal of Cardiology, 96, 611-616.
16. Holeyman, C. R., & Larson, D. F. (2001). Apoptosis in the ischemic-reperfused myocardium. Perfusion, 16, 491-502.
17. Saikumar, P., Dong, Z., Mikhailov, V., Denton, M., Weinberg, J. M., & Venkatachalam, M. A. (1999). Apoptosis: definition, mechanism and relevance to disease. American Journal of Medicine, 107, 489-506.
18. Porter, A. G., & Janicke, R. U. (1999). Emerging roles of caspase-3 in apoptosis. Cell Death and Differentiation, 6, 99-104.
19. Krupinski, J., Lopez, E., Marti, E., & Ferrer, I. (2000). Expression of caspases and their substrates in the rat model of focal cerebral ischemia. Neurobiology of Disease, 7, 332-342.